Aktieanalys

Medivir Q4 2024: TTP Continues to Improve - Redeye

{newsItem.title}

Redeye Publicerad: 16 Feb 2024 07:35

Redeye reviews Medivir's fourth quarter report, which disclosed further improvements in patient survival. After the two recent equity issues, the company is well funded to continue developing fostrox towards a phase IIb trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/980093/medivir-q4-2024-ttp-continues-improving?utm_source=finwire&utm_medium=RSS

Nyheter om Medivir

Läses av andra just nu

Om aktien Medivir

Senaste nytt